Company Overview
REGENXBIO Inc. operates as a clinical-stage biotechnology company dedicated to delivering functional genes to cells possessing genetic defects throughout the United States, utilizing its proprietary NAV Technology Platform which is based on adeno-associated virus gene delivery systems. The firm functions within the broader Healthcare sector and specifically targets the Biotechnology industry, positioning itself to develop advanced therapies for patients with rare genetic conditions. Currently, the company employs 371 individuals and maintains a market capitalization of $436.65M, while generating annual revenue of $170.44M. These valuation and revenue figures indicate that the company possesses a significant market presence within its niche, yet the market cap suggests it is still viewed as a high-growth, pre-profit entity rather than a mature cash cow, reflecting the capital-intensive nature of developing gene therapies.
Financial Health
The company reported revenue of $170.44M for the trailing twelve months, yet it recorded a net income of $-193,878,000 and an EBITDA of $-145,583,008, highlighting a substantial gap between top-line generation and profitability. This disparity reveals a cost structure heavily weighted toward research and development expenses and clinical trial costs that currently exceed the revenue generated from product candidates or licensing agreements. Free cash flow stands at $-79,794,752, indicating that the company is burning cash to fund operations and development, which limits immediate financial flexibility but is typical for clinical-stage firms in the biotechnology space. The gross margin is listed at -45.9%, the operating margin at -190.0%, and the profit margin at -113.8%, all of which reflect the extreme expenses inherent in bringing novel therapies to market before commercial scale is achieved. On the balance sheet, the company holds $230.07M in cash against $260.52M in debt, resulting in a debt-to-equity ratio of 253.59, which characterizes the balance sheet as highly leveraged relative to its equity base. Despite the high leverage, the current ratio of 2.38 indicates that the company maintains sufficient short-term liquid assets to cover its short-term obligations without immediate distress. Return on Equity is -107.0% and Return on Assets is -21.9%, metrics that demonstrate management is currently utilizing shareholder and asset bases to generate losses rather than returns, a common characteristic during the development phases of gene therapy assets.
Valuation Assessment
The trailing twelve months P/E ratio is N/A due to the lack of net income, while the forward P/E is -3.85, implying that the market is not pricing in immediate earnings growth but rather anticipating a path to profitability that has not yet materialized. The price-to-book ratio is 4.19, suggesting that the market values the company at more than four times its net asset value, which typically indicates a premium assigned to the intellectual property and potential of the NAV Technology Platform. Alternative valuation metrics such as the price-to-sales ratio of 2.56 and an EV/EBITDA of -3.21 provide context for investors analyzing the firm without relying on earnings multiples, showing that the company trades at a multiple of its sales despite negative earnings. The stock has traded between a 52-week high of $16.19 and a 52-week low of $5.04, meaning the current price sits at approximately 17.3% below the 52-week high if calculated relative to the high point, though the specific current price is not provided in the data to calculate the exact percentage. The beta value is 1.14, which indicates that the stock's price volatility is slightly higher than the broader market, reflecting the heightened sensitivity of biotechnology stocks to sector-specific developments and regulatory news.
Growth & Income
Revenue growth year over year is 43.0%, demonstrating a significant expansion in top-line activity, whereas earnings growth is N/A because the company has not yet achieved profitability to measure year-over-year earnings expansion. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that all earnings, including losses, are effectively reinvested into research, development, and clinical trials rather than distributed to shareholders. The absence of dividend payments and the reliance on cash reserves and financing to fund operations define the company's capital allocation strategy as growth-oriented rather than income-focused. Overall, the growth and income profile is defined by rapid revenue expansion coupled with negative earnings and no dividend distribution, presenting a high-risk, high-reward scenario typical of early-stage biotechnology ventures.